About the Event
Therapies made for a single patient, or for a small group of patients, are moving from proof of concept into the clinic. The first personalized CRISPR-based therapy, delivered with LNPs, showed what is possible.
Treating one patient is a breakthrough. Treating many, each with their own therapy, needs a model that works economically. How do we bring the cost per patient down, and what has to change in formulation, manufacturing and regulation to get there?
In this workshop, Evonik and LEON bring together speakers from academia and industry to discuss the science, the economics and the regulatory path of individualized and stratified LNP therapeutics. Expect scientific talks, open discussion and lunch.
Save the date and register today. The full agenda with all speakers will follow in the coming weeks.
Key learnings for participants- Evaluate the clinical potential of personalized LNP therapeutics beyond proof of concept
- Understand how formulation and manufacturing innovations can enable scalable individualized treatments
- Identify key economic factors that will determine commercial feasibility and patient access
- Gain perspective on the evolving regulatory environment for personalized and stratified therapies
Hosted by
Evonik CLS Member
Evonik goes beyond the boundaries of chemistry with its combination of innovative strength and leading technological expertise.
